Add to ORKGIdentification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulatio
Gut barrier dysfunction aggravates the progression of type 1 diabetes (T1D). Fingolimod (FTY720) ame...
FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that se...
Background Fingolimod (FTY720) is the first sphingosine-1-phosphate (S1P) receptor modulator approv...
Background: Fingolimod (FTY720), the first oral treatment for multiple sclerosis (MS), blocks immune...
Effect of FTY720 on expression of TLE family proteins. Expression of TLE1, TLE2, TLE3, and TLE4 usin...
FTY720 reduces expression of pro-inflammatory cytokines. A) Expression of IL-17 (n = 9), GMCSF (n = ...
FTY720 increases TCF7 expression in T cells. Expression of TCF7 in in vitro activated T cells from h...
Proposed model of interaction between S1P1 and Wnt signaling pathways. A) S1P1 receptor activation i...
Fingolimod is the first orally administered drug approved for the treatment of relapsing-remitting m...
FTY720, also known as fingolimod, is an orally administered sphingosine-1-phosphate (S1P) analogue t...
Fingolimod is an approved therapeutic option for patients with relapsing-remitting multiple sclerosi...
Background: Fingolimod (FTY720) is the first sphingosine-1-phosphate (S1P) receptor modulator approv...
Multiple sclerosis patient characteristics. All multiple sclerosis patients had relapsing-remitting ...
Fingolimod, a first-in-class oral sphingosine 1-phosphate receptor (S1PR) modulator, is approved in ...
Sphingosine-1 phosphate receptor 1 (S1PR1) is expressed by lymphocytes and regulates their egress fr...
Gut barrier dysfunction aggravates the progression of type 1 diabetes (T1D). Fingolimod (FTY720) ame...
FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that se...
Background Fingolimod (FTY720) is the first sphingosine-1-phosphate (S1P) receptor modulator approv...
Background: Fingolimod (FTY720), the first oral treatment for multiple sclerosis (MS), blocks immune...
Effect of FTY720 on expression of TLE family proteins. Expression of TLE1, TLE2, TLE3, and TLE4 usin...
FTY720 reduces expression of pro-inflammatory cytokines. A) Expression of IL-17 (n = 9), GMCSF (n = ...
FTY720 increases TCF7 expression in T cells. Expression of TCF7 in in vitro activated T cells from h...
Proposed model of interaction between S1P1 and Wnt signaling pathways. A) S1P1 receptor activation i...
Fingolimod is the first orally administered drug approved for the treatment of relapsing-remitting m...
FTY720, also known as fingolimod, is an orally administered sphingosine-1-phosphate (S1P) analogue t...
Fingolimod is an approved therapeutic option for patients with relapsing-remitting multiple sclerosi...
Background: Fingolimod (FTY720) is the first sphingosine-1-phosphate (S1P) receptor modulator approv...
Multiple sclerosis patient characteristics. All multiple sclerosis patients had relapsing-remitting ...
Fingolimod, a first-in-class oral sphingosine 1-phosphate receptor (S1PR) modulator, is approved in ...
Sphingosine-1 phosphate receptor 1 (S1PR1) is expressed by lymphocytes and regulates their egress fr...
Gut barrier dysfunction aggravates the progression of type 1 diabetes (T1D). Fingolimod (FTY720) ame...
FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that se...
Background Fingolimod (FTY720) is the first sphingosine-1-phosphate (S1P) receptor modulator approv...